Ethel Weld, MD

CRS:

JHU

Role:

Email:

eweld@jhmi.edu
  • Protocol chair, IMPAACT 2005
  • Protocol vice-chair, IMPAACT 2022
  • Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
  • Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
  • Member, Pharmacology Core, HPTN Laboratory Core
  • Member, TB in Pregnancy Working Group
  • Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More